人肿瘤细胞核苷酸切除修复蛋白表达与抗癌药耐药的相关性OA北大核心CSCDCSTPCD
Nucleotide Excision Repair Protein Levels vis-à -vis Anticancer Drug Resistance in 60 Human Tumor Cell Lines
背景与目的:核苷酸切除修复(Nucleotide excision repair,NER)是真核细胞中的DNA修复多酶系统,它可能与人肿瘤细胞对抗癌药的耐药有关.本实验将探讨NER蛋白(XPA,XPB,XPD和ERCC1)的表达与人肿瘤细胞耐药的关系.方法:采用western blot检测美国国家癌症研究所(National Cancer Institute,NCI)用于抗癌药筛选的60株人肿瘤细胞的ERCC1,XPA,XPB XPD表达,并与1…查看全部>>
Background ＆ Objective: Nucleotide excision repair (NER) is a multi-enzyme DNA repair system in eukaryotes. Several NER genes in this system including XPA, XPB, ERCC1, and ERCC2 (XPD) have been implicated in anticancer drug resistance in human tumor cells. This study was designed to investigate the relationship between the expression of NER protein and the drug-resistance of human tumor cell lines. Methods: In this study, The authors assessed the levels of t…查看全部>>
陈忠平;AretiMALAPETSA
中山大学肿瘤防治中心,广东,广州,510060Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, H3T 1E2,Canada
医药卫生
核苷酸切除修复肿瘤耐药烷化剂
Nucleotide excision repairAnti-cancer drug resistanceAlkylating agent
《癌症》 2002 (3)
233-239,7
(美国) National Cancer Institute Contract (加拿大)A private donation from Helen and Nicki Lang CMB-SUMS Scholarship Program (98-677)中山大学肿瘤防治中心启动基金项目(433)教育部留学回国人员基金项目(2000).